Ajinomoto Co Inc 2025 AR2
The report outlines Ajinomoto Co., Inc.'s performance and strategic initiatives for the fiscal year ended March 31, 2025. Key highlights include the advancement of its Medium-Term ASV Initiatives 2030 Roadmap, focusing on reducing environmental impact by 50% and extending healthy life expectancy. The company finalized the acquisition of gene therapy CDMO Forge Biologics and sold Ajinomoto Althea to optimize its business portfolio. Additionally, the report details progress in reducing Scope 1, 2, and 3 greenhouse gas emissions, and outlines its human capital strategy, including targets for female management representation.
Company: Ajinomoto Co Inc
Sector: Consumer Staples
Country: Japan
Year: 2025
Type: AR2
Pages: 292
Ajinomoto Co Inc
Annual Securities Report
The report outlines Ajinomoto Co., Inc.'s performance and strategic initiatives for the fiscal year ended March 31, 2025. Key highlights include the advancement of its Medium-Term ASV Initiatives 2030 Roadmap, focusing on reducing environmental impact by 50% and extending healthy life expectancy. The company finalized the acquisition of gene therapy CDMO Forge Biologics and sold Ajinomoto Althea to optimize its business portfolio. Additionally, the report details progress in reducing Scope 1, 2, and 3 greenhouse gas emissions, and outlines its human capital strategy, including targets for female management representation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 3:
Women in Management
Net Zero Target
Employees